The Trump administration released its budget proposal for fiscal year 2026, which would chop roughly 40% from the NIH budget over the current fiscal year — a proposal that might not find much support on Capitol Hill.
Mabwell (Shanghai) Bioscience Co. Ltd. on May 30 gained Chinese approval of Mailisheng (albipagrastim alfa; 8MW-0511) as a subcutaneous injection to treat febrile neutropenia induced by myelosuppressive anticancer treatment, such as radiotherapy and chemotherapy.
Samsung Medical Center spinoff Aimedbio Inc. announced raising ₩51.1 billion (US$37.15 million) in pre-IPO funding to advance its portfolio of clinical and preclinical antibody-drug conjugate (ADC) candidates.
Biopharma’s nonprofit deal and grant activity continues to settle into a post-pandemic rhythm, with both showing a sustained decline from the elevated levels seen during and even after the COVID-19 era.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Beam, Zymeworks.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biocryst, Coherus, Hansoh, Novo Nordisk, Regeneron, Sumitomo.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Avadel, Biolinerx, Enterome, Faron, GC Biopharma, Genentech, Merck, Pfizer, Regeneron, Roche, Sanofi, Summit.
RSS
